Evidence map›Paper›PMID 41839513›Full record

ArticleStatistics in medicine2026

On Window Mean Survival Time With Interval-Censored Data.

Takuto Iijima, Tomotaka Momozaki, Shuji Ando

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Statistics in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Takuto IijimaDepartment of Information Sciences, Graduate School of Science and Technology, Tokyo University of Science, Chiba, Japan.
Tomotaka MomozakiDepartment of Information Sciences, Faculty of Science and Technology, Tokyo University of Science, Chiba, Japan.ORCID https://orcid.org/0000-0001-6735-0804
Shuji AndoDepartment of Information Sciences, Faculty of Science and Technology, Tokyo University of Science, Chiba, Japan.ORCID https://orcid.org/0000-0003-1663-1897

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, cancer clinical trials have increasingly encountered non proportional hazards (NPH) scenarios, particularly with the emergence of immunotherapy. In randomized controlled trials comparing immunotherapy with conventional chemotherapy or placebo, late difference and early crossing survival curves scenarios are commonly observed. In such cases, window mean survival time (WMST), the area under the survival curve within a pre-specified interval

Indexed as

NeoplasmsComputer SimulationHumansImmunotherapyProgression-Free SurvivalProportional Hazards ModelsRandomized Controlled Trials as TopicSurvival RateKaplan–Meier methodmid‐point imputationnonparametric estimatornon‐proportional hazardssurvival data

Identifiers

PMID41839513
PMCPMC12991874

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.